Wire · opportunities
FDA Panel Recommends Compounding Approval for Wolverine Stack Peptides
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 27 July 2026 · Fusion42 review
The FDA's Pharmacy Compounding Advisory Committee voted narrowly to recommend adding six unapproved peptides, including BPC-157 and TB-500, to the list of ingredients allowed in compounded medications. The move aims to regulate black-market peptide sales through licensed pharmacies, but opponents warn it risks creating the false impression of FDA approval and could fuel marketing of unproven recovery and anti-ageing treatments.
This Wire brief sits within Fusion42's coverage of Biotech, and 9 sources have reported it between 23 Jul 2026 and 28 Jul 2026.
◆ ◆ The Wire takeaway
Peptide wellness companies and telemedicine platforms are gaining a legal supply route through compounding pharmacies, but only if they don't claim FDA approval—which compounding clearance is not. The next six months will determine whether you can build a compliant retail model here, or whether the 'FDA-approved' marketing claim becomes your liability when regulators distinguish between what was approved to compound and what was proven to work.
◆ Coverage
9 sources · first reported 23 Jul 2026 · latest 28 Jul 2026
◆ Topics